Key Points
- Joseph Sardano, CEO of Sensus Healthcare, purchased 25,000 shares on November 18 at an average price of $4.03 ($100,750 total), increasing his stake to 1,200,293 shares — a 2.13% ownership rise disclosed in an SEC filing.
- Sensus shares trade around $4.12 with a market cap of about $67.6M; the company recently beat quarterly expectations (EPS -$0.06 vs. -$0.12 est., revenue $6.88M vs. $6.31M) but still has negative margins, and analysts hold a consensus Hold rating with a $8.00 target.
Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) CEO Joseph Sardano bought 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 18th. The stock was purchased at an average cost of $4.03 per share, with a total value of $100,750.00. Following the completion of the transaction, the chief executive officer owned 1,200,293 shares in the company, valued at approximately $4,837,180.79. This trade represents a 2.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Sensus Healthcare Price Performance
Shares of SRTS traded up $0.08 during mid-day trading on Thursday, reaching $4.12. 37,682 shares of the company's stock were exchanged, compared to its average volume of 167,338. The stock has a market capitalization of $67.61 million, a PE ratio of -68.65 and a beta of 1.38. The business's fifty day simple moving average is $3.44 and its 200-day simple moving average is $4.06. Sensus Healthcare, Inc. has a 52-week low of $3.03 and a 52-week high of $9.33.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.06. The firm had revenue of $6.88 million during the quarter, compared to the consensus estimate of $6.31 million. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. Equities research analysts predict that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current year.
Wall Street Analyst Weigh In
SRTS has been the topic of a number of recent analyst reports. Zacks Research raised shares of Sensus Healthcare from a "strong sell" rating to a "hold" rating in a research note on Wednesday, October 22nd. Weiss Ratings reiterated a "sell (d)" rating on shares of Sensus Healthcare in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Sensus Healthcare from a "sell" rating to a "hold" rating in a research note on Saturday, November 8th. Lake Street Capital cut their price objective on shares of Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Finally, HC Wainwright lowered their target price on shares of Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sensus Healthcare has a consensus rating of "Hold" and a consensus target price of $8.00.
View Our Latest Stock Report on Sensus Healthcare
Hedge Funds Weigh In On Sensus Healthcare
A number of large investors have recently modified their holdings of SRTS. Kingstone Capital Partners Texas LLC purchased a new stake in shares of Sensus Healthcare during the 2nd quarter valued at about $3,170,000. Divisadero Street Capital Management LP lifted its position in shares of Sensus Healthcare by 459.4% during the second quarter. Divisadero Street Capital Management LP now owns 324,673 shares of the company's stock worth $1,539,000 after purchasing an additional 266,635 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Sensus Healthcare by 35.3% in the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company's stock valued at $2,225,000 after purchasing an additional 122,746 shares during the period. Pacific Ridge Capital Partners LLC grew its holdings in Sensus Healthcare by 26.1% during the 3rd quarter. Pacific Ridge Capital Partners LLC now owns 573,389 shares of the company's stock valued at $1,800,000 after purchasing an additional 118,628 shares in the last quarter. Finally, Meros Investment Management LP acquired a new position in Sensus Healthcare in the 1st quarter worth $419,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.
About Sensus Healthcare
(
Get Free Report)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
